We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hood
You really ate an odd ball.
Note carefully below the reply l received from Sareum
Read and try to understand
'Thank you for your email and interest in supporting Sareum, which is much appreciated.
As noted in our RNS of March 12, we are currently assessing funding sources. Should we pursue an equity fundraise, as we have done before we would anticipate giving existing shareholders the opportunity to participate. As we have done in the past, we would expect this would be through one of the retail platforms such as Wrap or Bookbuild. If this is the case, then full details will be announced to the market, and we will ensure that in addition we send you a copy of that announcement.'
With best regards, Sareum IR'
'We are assessing funding sources,'
'Should we pursue an equity fundraise'
From what is written above Sareum have more than one option of how to raise funds.
First part of phase 1 ie phase 1 completed with expected top line results.
That from dualified people a bit further up the knowledge tree than you are likely to ever reach.
You know nothing of the company and nothing about the biotech business.
You post nothing of substance just the same old childish drivel.
I remember the Puma posting.
Sareum will have the option to onlicence on phase1a data alone or raise funds to progress to phase1b
At phase 1a value less with smaller upfront payment. Phase 1b higher value larger upfront payment.
Most likely out come will be an on license during phase 1b trials in my honest opinion.
Sareum will overcome this problem irrespective of what ever you post here.
Your only interest is the SP falling.
You spout absolute unsubstantiated rubbish to push your agenda.
Have a good day and your time frame with regards of your short working are rapidly coming to an end.
S
Know the feeling franky99
Was 3,200% up on GGP by late 2019 having been invested since 2014, but have seen over £650k in profit evaporate ever since! 😢
Post below relating to Aurora +FLT3
https://pubmed.ncbi.nlm.nih.gov/34446858/
Although it does not mention Sareum l am pretty sure it is the Sareum compound.
Why would l think that?
CCT245738. First numbers relate to heterocyclic rings and molecule structure.
There was no advancement in this as halted by solubility issues for sufficient amounts if the compound to be taken intravenously.
An option would be via the oral route.
Unfortunately to continue development of SDC-1801 funds were diverted away from progress of
Aurora FLT3.
Nothing of any significance here regarding future funding, it is shelved until we are notified otherwise.
Https://www.factmr.com/report/immune-checkpoint-inhibitor-market#:~:text=Immune%20Checkpoint%20Inhibitor%20Market%20Outlook,14.7%25%20from%202024%20to%202034.
Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671062/#:~:text=LATTICE%2DUC%20was%20a%20double,more%20conventional%20or%20biologic%20therapies.
Hood,
'It’s probably not enough, realistically. You really want it to get you to the end of Ph1b. How long is that going to take? 2-3 years at least at the pace these guys typically operate, I’d say.'
What a load of tosh you post here.
Plan is to complete phase1b at end of 2024. This is notified to us numerous times via RNS'S. These statements have far more credibility than any of your ill conceived opinions.
One reason that Sareum would have used this facility is to prove that they have the ability to access finance to fund the stage1 trial.
This is a requirement of a CTA application. Without this access to funding the CTA application would never have been granted.
The first part ie 1a of the trial is basically complete and awaiting final detailed results that will enable from the point of view of satisfactory safety results to enter into phase1b.
With regards to finance our development of SDC1801 we are at later stage than end of preclinical. Top line results are expected as stated in Sareums RNS.
I would certainly take this having credibility over the complete and utter ill conceived drivel that you post here.
As for the 4 million required you make no sense.
You have stated when asked previously why a figure of 4 million and what will it be spent on and you ludicrously reply with directors salaries.
Sareum are working at seeking an alternative form of financing. This in reality should present no real problems on conclusion of 1a safety data along with biomarker data.
I am sure you understand the importance and knock on effect for this data not only for 1801 but also 1802.
If you cannot comprehend this or more likely refuse to acknowledge this fact then tt is evident that your knowledge and understanding of drug discovery, preclinical development, CTA application, phase1,2 and 3 stages of success with corresponding increase in value at each stage are at best very poor.
Regards.
Reality10, l would like to think that the BoD do visit this BB and dramatically change their attitude and communicate to us in such a way that they take on constructive criticism and address these issues, signalling to us that we are not investors that are bring taken for granted.
Surely that is in no way being unreasonable.
Regards
Again not difficult Robinhood. Set the bar low at 500k or enough to cover the completion of the first trials, with a cap at 3m. Then you’re not embarrassed if you come in at 800k or 1.2m if it’s over subscribed. That word alone would be positive and buy the company more time, could also throw in a future option for those that subscribe for the placing.
Ballater
I was in ballayer, braemar, for 12 weeks with work, I would loved to have done that SOG
Reality10, you had an opportunity to sit down in front of the board at the AGM. Why didn't you attend the AGM and vent your views then?
Regards
Reality couldn't agree more well said we'll put
Rgds
Ray
i would love to be able to sit down in front of the board and just say,, “ seriously guys what the hell are you doing? we are on the cusp of greatness but your utter incompetence keeps ******* it up. get your game faces on, think about your decisions , at the moment your coming across as a bunch of clowns, drop the arrogance and start communicating and showing some respect to the investors that are bank rolling you. if i didn’t know better i say you are coming across as deliberately trying to sabotage the company and share holder value, as no one in their right mind would keep making these dreadful decisions, your suppose to be experts but your coming across as amateurs and that’s being polite”
Robin I agree with you about raising more than enough money so they know they've got it covered & not have to go through thus pinacolada again
Hood
Why do they have to raise several million quid?
Regards
The Hood
' The problem, if you don’t raise enough, is that everyone knows there needs to be a further raise. They have to raise several million quid this time round else there’s no point.'
In what capacity are you to state '
'They have to raise several million quid this time round else there’s no point.'
Regards
The Hood, why does there need to be a furthere raise. This ' everybody knows' can you tell us who this everybody is? Do you know who they are?
Regards
800% fat fingers👍
Bottom draw is open...hope this share doesnt get put in ..been a rollercoaster...could have sold 8800% up...now down...nother lesson learnt in the world of aim....take ya profits...hope it comes good. gla.
Franky
That would makes sense rioutd777.
Not overly sure if they could issue new shares, but then again that is what they have been doing with Riverfort.
Regards
Not difficult is it, six month deferral of salaries and approach the present investor base for capital. I’m sure amongst the Pi’s we could raise 300k or 500k without breaking a sweat. I’d stick more in if there was clear plan put forward. No need to go the whole hog, just initiate a raise as each milestone is passed.
Good morning PCS1954
Yes, sareum indeed need to release comprehensive detail. That will be a first for them.
Although a tad different to us, an interesting deal below for BMS.
https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-RayzeBio-Adding-Differentiated-Actinium-Based-Radiopharmaceutical-Platform/default.aspx#:~:text=Based%20Radiopharmaceutical%20Platform-,Bristol%20Myers%20Squibb%20Completes%20Acquisition%20of%20RayzeBio,Differentiated%20Actinium%2DBased%20Radiopharmaceutical%20Platform&text=Category%3A&text=PRINCETON%2C%20N.J.%2D%2D(BUSINESS%20WIRE,its%20acquisition%20of%20RayzeBio%2C%20Inc.
Regards
Thanks for sharing, likewise, I've been speaking with some fellow attendees of the AGM (respecting their privacy, I won't name) and was getting that indication.
Hopefully, the BoD are close to resolving and perhaps that'swhy in the RNS the interim results announcement were noted as w/c 25th, rather than a specific date, so perhaps as has been suggested on the bb a targeted timeline!
Again, these results need to have comprehensive detail similar to JR's statement yesterday and not the ambiguity of the RNS of the 12th - so whoever, writes, authorises etc.. lets get it right please!!
Oh and yes, spot on with "person " analogy.
To one and all genuine Sareum shareholders, enjoy your weekend!
@ Andy. let me know if you are still up for a meet next week as I will back down in Cornwall, next weekend for Easter - no probs if you leave until after.
GLA
Sad 10 years on speaks volumes slow and late to the party really do spring to mind, how much data have you actually seen read on SDC-1801 since 2014 to make any sort of judgement. SDC-1801 is akin to Brepocitinib with plenty of data to read that's more comparative. The arena is now so much more competitive compared with a few year ago.
Agreed there's been plenty of delays along the way but not all external, deciding to switch to the tablet route thus further delaying filing for CTA spring to mind even Edison flagged this as a strange move at the time /
I still believe they wanted SDC-1801 gone preclinical but obviously not enough data to support a license deal....
Anyway onwards and upwards hopefully some good news next week to lift the SP.
With regards to raising finance.
Try getting a mortgage or loan on a property and what is required is a market valuation. The data from this valuation will allow within banking practices a percentage of loan that they will lend.
No valuation no mortgage.
That is an extremely simplified analogy of where Sareum sit.
Had our market cap stayed above the 2 pounds a share mark and not been hammered by the return of 737 to CPF or the MHRA being inept with inexperienced staff with consequently being unable to grant approval at what SP would you put on Sareum with the considerable progress and early phase1 a data results?
Has the price prepared to be paid for a potential best in class autoimmune inhibitor dropped?
Maybe a tad yes but nowhere near the amount to justify going from 150 million to a 15 million pound market cap.
Poor finance has caused a very damaging decline.
Are Tim.and Co playing a very tight game with the interested parties?
Full phase 1a data is expected Q2. If we are funded to cover the end of this then no big problem.
Tim and Co should have included in the RNS on failure of drawing down these funds the amount of cash runway we have left.
This in my opinion being omitted from the RNS is appalling.
Regards and am now blowing the froth off of a couple.